Investigational drug · Phase 2
CYH33
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM), Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "CYH33"
First trial start
2021
Oct 11, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CYH33", any sponsor or status.
Conditions studied
As listed on its trial records.
- PIK3CA-Related Overgrowth Spectrum (PROS)
- PIK3CA-related Vascular Malformations (PRVM)
- Ovarian Cancer
- Recurrent Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CYH33" as an intervention, largest first.
Haihe Biopharma Co., Ltd.Industry
NCT04856371 · 228 participants (planned) · Start Apr 2021 · Primary completion Mar 2022
Drug: CYH33; Fulvestrant and 2 more · For: Advanced Breast Cancer
Haihe Biopharma Co., Ltd.Industry
NCT03544905 · 206 participants · Start Jul 5, 2018 · Primary completion Dec 4, 2024
Drug: CYH33 for tablet · For: Advanced Solid Tumors
Sites: Hefei, China; Lu'an, China; Beijing, China · 30 sites in all
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)Pivotal-lookingRecruiting
Haihe Biopharma Co., Ltd.Industry
NCT06975618 · 141 participants (planned) · Start Aug 22, 2023 · Primary completion Dec 31, 2029
Drug: CYH33; Placebo · For: PIK3CA-Related Overgrowth Spectrum (PROS); PIK3CA-related Vascular Malformations (PRVM)
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 15 sites in all
- A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell CarcinomaActive, not recruiting
Haihe Biopharma Co., Ltd.Industry
NCT05043922 · 93 participants · Start Oct 11, 2021 · Primary completion Jul 31, 2024
Drug: CYH33 · For: Ovarian Cancer; Recurrent Cancer
Sites: Beijing, China; Chongqing, China; Guangdong, China · 36 sites in all
Haihe Biopharma Co., Ltd.Industry
NCT04586335 · 24 participants · Start Sep 28, 2020 · Primary completion Feb 15, 2023
Drug: CYH33 · For: Ovarian Cancer; Breast Cancer; Solid Tumor and 2 more
Sites: New Haven, Connecticut; Dallas, Texas; Houston, Texas · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dapagliflozin alleviates CYH33-induced hyperglycemia and preserves antitumor immunity against ovarian cancer in type 1 diabetic mice.
Sun J, Xu L, Qu H, et al. · Life Sci 2026
- Targeting PI3Kα with Small Molecules: Progress and Challenges in Tumor Treatment.
Jia W · Curr Issues Mol Biol 2026
- Targeting intrinsic and CAF-mediated signaling by PI3Kα inhibitor CYH33 attenuated metastasis in lung squamous cell carcinoma.
Ma XY, Deng JT, Cao ZR, et al. · Acta Pharmacol Sin 2026
- PI3K-dependent GAB1/Erk phosphorylation renders head and neck squamous cell carcinoma sensitive to PI3Kα inhibitors.
Zhang X, Xu J, Wang X, et al. · Cell Death Dis 2025
- An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group.
Shigeta S, Shimada M, Suzuki S, et al. · JMA J 2023
- Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R.
Qi WL, Li HY, Wang Y, et al. · Acta Pharmacol Sin 2023
Also in development for PIK3CA-Related Overgrowth Spectrum (PROS)
- RLY-2608Phase 21 trial
Relay Therapeutics, Inc. · PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.